Showing 501 - 520 results of 646 for search '"tyrosine"', query time: 0.06s Refine Results
  1. 501

    STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC by Shiyu Huang, Xuke Qin, Shujie Fu, Juncheng Hu, Zhengyu Jiang, Min Hu, Banghua Zhang, Jiachen Liu, Yujie Chen, Minghui Wang, Xiuheng Liu, Zhiyuan Chen, Lei Wang

    Published 2025-01-01
    “…Furthermore, STAMBPL1 silencing and the tyrosine kinase inhibitor (TKI) sunitinib also exhibited a synergistic effect on the suppression of KIRC. …”
    Get full text
    Article
  2. 502

    Ewing sarcoma – pathomechanisms, standard treatment and new therapeutic perspectives by Wojciech Zezuliński, Filip Woliński, Julia Zyśk, Mateusz Korga, Jakub Klas, Jacek Baj, Eliasz Dzierżyński

    Published 2025-01-01
    “…The paper discusses, among other things, treatment attempts based on the role of the EWS-FLI1 protein, epigenetics, tyrosine kinase inhibitors, immunotherapies and the use of nanomedicine and viruses, as well as the difficulties associated with their application. …”
    Get full text
    Article
  3. 503

    Analysis of the Muscle Structure and Protein Composition of Different Varieties of Cultured Large Yellow Croaker (Larimichthys crocea) by Yuan MA, Quanyou GUO, Yao ZHENG, Weibo SUN, Liu YANG, Xiaoyan SONG

    Published 2025-02-01
    “…The leucine, lysine, phenylalanine, and tyrosine contents in the muscles of all five varieties were higher than the WHO/FAO standards. …”
    Get full text
    Article
  4. 504

    Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

    Published 2025-02-01
    “…Proton pump inhibitors (PPIs) have shown potential in lowering soluble FMS-like tyrosine kinase-1 (sFlt-1) levels and enhancing endothelial function, but clinical trials have been inconsistent. …”
    Get full text
    Article
  5. 505

    T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy by Meng-Tung Hsu, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Leo Hansmann, Leo Hansmann, Leo Hansmann, Leo Hansmann, Thomas Blankenstein

    Published 2025-01-01
    “…BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. …”
    Get full text
    Article
  6. 506

    Modulated Light Elicitation and Associated Physiological and Molecular Processes in Phenolic Compounds Production in <i>Ocimum basilicum</i> L. Microgreens by Gabriel-Ciprian Teliban, Naomi-Eunicia Pavăl, Gabriela Mihalache, Marian Burducea, Vasile Stoleru, Andrei Lobiuc

    Published 2025-01-01
    “…Moreover, in the red cultivar, gene expression was enhanced, 1.3–6.3 fold for genes coding for enzymes involved in phenylpropanoid synthesis pathways, such as phenylalanine ammonia lyase (PAL), tyrosine aminotransferase (TAT), Catechol-O-methyltransferase (COMT) and rosmarinic acid synthetase (RAS). …”
    Get full text
    Article
  7. 507

    Characterization of Flakes Made in Corn Flour (Zea Mays) and Pumpkin (Cucurbita Moshcata) with Addition of Soybean Flour (Glicine Max) by Lucia Saraswati, Fauzan Azima, Daimon Syukri

    Published 2023-09-01
    “…(color 4.35; aroma 3.65; taste 4.10; texture 3, 70) with a total value of 9.72% amino acids and the types of amino acids identified are glutamic acids, leucine, aspartic acid, arginine, alanine, phenylalanine, valine, serine, isoleucine, tyrosine, threonine, lysine, histidine, glycine, and methionine. . threonine, lysine, histidine, glycine, and methionine. . threonine, lysine, histidine, glycine, and methionine.   …”
    Get full text
    Article
  8. 508

    The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

    Published 2011-01-01
    “…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). …”
    Get full text
    Article
  9. 509

    Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO by Vidya Narayanaswami PhD, Kenneth Dahl PhD, Vadim Bernard-Gauthier PhD, Lee Josephson PhD, Paul Cumming PhD, Neil Vasdev PhD

    Published 2018-09-01
    “…We now review the lead structures in radiotracer development for PET studies of neuroinflammation targets for neurodegenerative diseases extending beyond TSPO, including glycogen synthase kinase 3, monoamine oxidase-B, reactive oxygen species, imidazoline-2 binding sites, cyclooxygenase, the phospholipase A2/arachidonic acid pathway, sphingosine-1-phosphate receptor-1, cannabinoid-2 receptor, the chemokine receptor CX3CR1, purinergic receptors: P2X 7 and P2Y 12 , the receptor for advanced glycation end products, Mer tyrosine kinase, and triggering receptor expressed on myeloid cells-1. …”
    Get full text
    Article
  10. 510

    FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

    Published 2025-01-01
    “…Abstract The crosstalk between cancers and the immune microenvironment plays a critical role in malignant progression. FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). …”
    Get full text
    Article
  11. 511

    EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report by Hiroyuki Fujii, MD, Yusuke Okuma, MD, PhD, Makoto Hirata, MD, PhD, Yuki Shinno, MD, PhD, Tatsuya Yoshida, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Yuichiro Ohe, MD, PhD

    Published 2025-02-01
    “…Remarkably, despite the presence of EGFR mutation, the response to EGFR-tyrosine kinase inhibitor was poor, whereas the response to cytotoxic anticancer drugs and immunotherapy was favorable. …”
    Get full text
    Article
  12. 512

    Enhancing the growth and essential oil components of Lavandula latifolia using Malva parviflora extract and humic acid as biostimulants in a field experiment by Mervat El-Hefny, Mahmoud Khattab Hussien

    Published 2025-01-01
    “…Also, alanine, ammonia, aspartic acid, glutamic acid, glycine, and tyrosine were the ME’s most prominent nitrogenous and amino acid components. …”
    Get full text
    Article
  13. 513

    Multiomics characterization of breast angiosarcoma from an Asian cohort reveals enrichment for angiogenesis signaling pathway and tumor-infiltrating macrophages by Tun Kiat Ko, Zexi Guo, Bavani Kannan, Boon Yee Lim, Jing Yi Lee, Zhimei Li, Elizabeth Chun Yong Lee, Bin Tean Teh, Bin Tean Teh, Jason Yongsheng Chan, Jason Yongsheng Chan, Jason Yongsheng Chan

    Published 2025-01-01
    “…These genes were functionally annotated and were enriched in cancer-related pathways such as regulation of cell differentiation, VEGFR and receptor tyrosine kinases signaling pathways. By NanoString gene expression profiling, ASB, compared to AS-HN, were enriched for angiogenesis, notch signaling and metastasis-associated matrix remodeling pathways. …”
    Get full text
    Article
  14. 514

    Molecular Alterations of KIT Oncogene in Gliomas by Ana L. Gomes, Jorge S. Reis-Filho, José M. Lopes, Olga Martinho, Maryou B. K. Lambros, Albino Martins, Fernando Schmitt, Fernando Pardal, Rui M. Reis

    Published 2007-01-01
    “…KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes. …”
    Get full text
    Article
  15. 515

    hnRNPH1 Inhibits Influenza Virus Replication by Binding Viral RNA by Ruixue Xue, Danqi Bao, Tianxin Ma, Shiqi Niu, Zihua Wu, Xuehua Lv, Yunxiang Zhang, Guanlong Xu, Dawei Yan, Zhifei Zhang, Xue Pan, Minghao Yan, Qiaoyang Teng, Chunxiu Yuan, Zejun Li, Qinfang Liu

    Published 2024-12-01
    “…Mutation of the key residues tryptophan and tyrosine in RRM1 and RRM2 abolished the binding affinity to viral RNA and the suppression of polymerase activity of the influenza virus. …”
    Get full text
    Article
  16. 516

    Specific plasma metabolite profile in intestinal Behçet’s syndrome by Cheng-cheng Hou, Hua-fang Bao, Chun-hui She, Hua-yu Chen, Guan-xing Pan, Hua-ning Chen, Hong-bing Rui

    Published 2025-01-01
    “…In addition, a total of 103 significant metabolites were selected to distinguish active IBS from inactive IBS patients. Tyrosine metabolism, dopaminergic synapse and neuroactive ligand-receptor interaction were found to be closely related to the disease activity of IBS. …”
    Get full text
    Article
  17. 517

    HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven Parkinson's disease by Khang-Yen Pham, Shristi Khanal, Ganesh Bohara, Nikesh Rimal, Sang-Hoon Song, Thoa Thi Kim Nguyen, In-Sun Hong, Jinkyung Cho, Jong-Sun Kang, Sooyeun Lee, Dong-Young Choi, Simmyung Yook

    Published 2025-02-01
    “…Additionally, PLGA@CAY@Lf NPs treatment normalized dopamine and tyrosine hydroxylase levels, reduced neuroinflammation, and improved behavioral impairments. …”
    Get full text
    Article
  18. 518

    The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity by Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo

    Published 2022-06-01
    “…Abstract Aims Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. …”
    Get full text
    Article
  19. 519

    Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort by Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben

    Published 2025-02-01
    “…Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. …”
    Get full text
    Article
  20. 520

    Hydrogen-Rich Saline Attenuates Acute Renal Injury in Sodium Taurocholate-Induced Severe Acute Pancreatitis by Inhibiting ROS and NF-κB Pathway by Qiao Shi, Kang-Shu Liao, Kai-Liang Zhao, Wei-Xing Wang, Teng Zuo, Wen-Hong Deng, Chen Chen, Jia Yu, Wen-Yi Guo, Xiao-Bo He, Ablikim Abliz, Peng Wang, Liang Zhao

    Published 2015-01-01
    “…Results showed that hydrogen-rich saline attenuated the following: (1) serum Cr and BUN, (2) pancreatic and renal pathological injuries, (3) renal MDA, (4) renal MPO, (5) serum IL-1β, IL-6, and renal TNF-α, HMGB1, and (6) tyrosine nitration, IκB degradation, and NF-κB activation in renal tissues. …”
    Get full text
    Article